Pulmonx Appoints New Chief Medical Officer
Ticker: LUNG · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1127537
| Field | Detail |
|---|---|
| Company | Pulmonx Corp (LUNG) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $450,000, $1,375,000, $1,350,000 b, $200,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, medical-devices, personnel
TL;DR
Pulmonx just hired a new CMO, Dr. Michael J. Zwick, from Inspire Medical.
AI Summary
Pulmonx Corporation announced on April 2, 2024, the appointment of Dr. Michael J. Zwick as Chief Medical Officer. Dr. Zwick previously served as Chief Medical Officer at Inspire Medical Systems, Inc. and has extensive experience in the medical device industry, particularly in pulmonary and sleep-related conditions.
Why It Matters
The appointment of a new Chief Medical Officer with relevant experience could signal a strategic focus on product development and clinical strategy for Pulmonx's respiratory care solutions.
Risk Assessment
Risk Level: low — This filing is an 8-K reporting a routine executive appointment, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Pulmonx Corporation (company) — Registrant
- Dr. Michael J. Zwick (person) — Appointed Chief Medical Officer
- Inspire Medical Systems, Inc. (company) — Dr. Zwick's former employer
- April 2, 2024 (date) — Date of Report
FAQ
What is the effective date of Dr. Michael J. Zwick's appointment as Chief Medical Officer?
The filing does not explicitly state an effective date for Dr. Zwick's appointment, but it is reported as of April 2, 2024.
What was Dr. Zwick's previous role before joining Pulmonx?
Dr. Zwick previously served as Chief Medical Officer at Inspire Medical Systems, Inc.
What is Pulmonx Corporation's principal executive office address?
Pulmonx Corporation's principal executive offices are located at 700 Chesapeake Drive, Redwood City, CA 94063.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for Pulmonx Corporation?
The Standard Industrial Classification (SIC) code for Pulmonx Corporation is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 1,613 words · 6 min read · ~5 pages · Grade level 11.8 · Accepted 2024-04-02 16:08:42
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value LUNG The Nasdaq Stock Market
- $450,000 — e will be paid an annual base salary of $450,000 and will be eligible to receive an annu
- $1,375,000 — the Company's common stock with a value $1,375,000 to be determined using a Black-Scholes
- $1,350,000 b — he "RSU"), to be determined by dividing $1,350,000 by the trailing 60-day average closing pr
- $200,000 — y will pay Mr. Joshi a sign-on bonus of $200,000, less applicable withholdings (the "Sig
Filing Documents
- lung-20240402.htm (8-K) — 40KB
- exhibit101-employmentoffer.htm (EX-10.1) — 32KB
- exhibit991-pressreleasecfo.htm (EX-99.1) — 9KB
- image_0a.jpg (GRAPHIC) — 9KB
- image_1.jpg (GRAPHIC) — 387KB
- 0001127537-24-000039.txt ( ) — 727KB
- lung-20240402.xsd (EX-101.SCH) — 2KB
- lung-20240402_lab.xml (EX-101.LAB) — 21KB
- lung-20240402_pre.xml (EX-101.PRE) — 12KB
- lung-20240402_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 2, 2024, the Company issued a press release announcing the matters described in Item 5.02 above. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Offer Letter, dated March 19, 2024 by and between Mehul Joshi and Pulmonx Corporation 99.1 Press Release of Pulmonx Corporation, dated April 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pulmonx Corporation Dated: April 2, 2024 By: /S/ DAVID LEHMAN David Lehman General Counsel